Plasma Fractionation Market to Grow at a CAGR of 8.8% over 2025 to 2032; Strong Healthcare Infrastructure to Drive Market Growth

The global plasma fractionation market size was valued at USD 37.31 billion in 2024. The market is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a CAGR of 8.8% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Plasma Fractionation Market Size, Share & Industry Analysis, By Product (Albumin, Immunoglobulin [Intravenous Immunoglobulin {IVIG}, and Subcutaneous Immunoglobulin {SCIG}], Coagulation Factors [Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, and Others], Protease Inhibitors, and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Regional Forecast, 2025-2032”.

Plasma fractionation extracts key proteins from human plasma to produce life-saving therapies, including immunoglobulins, albumin, and coagulation factors. These treatments are essential for managing immune disorders, clotting deficiencies, and critical medical conditions. Advancements in plasma fractionation, coupled with the rising incidence of autoimmune and bleeding disorders, are propelling market growth. The increasing need for plasma-derived therapies to manage immune deficiencies and critical injuries further strengthens market expansion.

The market grew during the COVID-19 pandemic due to increased research on immunoglobulins and albumin for COVID-19 treatment. However, plasma collection disruptions in 2021 slowed market growth. By 2022, supply improvements and new product launches fueled a strong rebound, with steady revenue growth continuing into 2023 and 2024.

Octapharma AG FDA Approval to Boost its Presence in the Plasma-Based Therapy Market

Octapharma AG received U.S. FDA extended approval for wilate in December 2023, expanding its use for routine prophylaxis in patients 6+ years to reduce bleeding frequency, strengthening its presence in the plasma-based therapy market.

High Burden of Immunodeficiency and Rare Disorders to Drive Market Growth

The increasing incidence of conditions such as AIDS and Sjögren’s syndrome is driving demand for plasma-derived therapeutics. With 39.9 million people living with HIV in 2023, according to the U.S. Department of Health & Human Services, the need for immunoglobulins and other plasma-based treatments continues to grow. Moreover, rare conditions such as Hemophilia A & B and von Willebrand disease (VWD) are increasing the demand for plasma-derived clotting factors. In 2022, according to World Federation of Hemophilia Report 2022, over 351,000 individuals worldwide were reported to have these disorders, fueling plasma fractionation market growth. However, recombinant therapies eliminate the risk of blood-borne infections, making them a safer and more reliable option, thereby restricting the market growth.

Industry Participants Focus on Partnerships to Expand their Facility

The global plasma fractionation market is highly consolidated, with CSL Behring and Takeda Pharmaceutical leading in 2024 due to strong R&D investments, plasma collection expansion, and strategic partnerships. In December 2022, CSL Behring launched a Victoria, Australia, facility, increasing plasma processing capacity ninefold to 9.2 million liters annually.

List of Key Players Mentioned in the Report:

• CSL Behring (CSL) (U.S.)
• Grifols, S.A (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Kedrion S.p.A (Italy)
• Octapharma (Switzerland)
• ADMA Biologics, Inc. (U.S.)
• Sartorius AG (Germany)
• LFB (France)

Key Industry Development

• September 2024- In a strategic move, GC Biopharma USA, Inc. introduced ALYGLO (IVIG) for primary humoral immunodeficiency (PI) in adults (17+), expanding its immunoglobulin product portfolio.

Further Report Findings

• With USD 20.96 billion in 2024 revenue, North America is poised to capture the key plasma fractionation market share, fueled by strong healthcare infrastructure, technological advancements in plasma-derived therapies, and increased plasma collection efforts. Takeda’s BioLife Plasma Services expanded its U.S. network in March 2023, strengthening plasma supply and fueling market growth.
• The Asia Pacific plasma fractionation market is expanding due to increased pharmaceutical investments, rising chronic diseases, and improved healthcare access. In May 2023, Plasma Gen Biosciences opened a plasma manufacturing facility in Bangalore, enhancing regional supply.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

Table of Segmentation